gms | German Medical Science

127. Kongress der Deutschen Gesellschaft für Chirurgie

Deutsche Gesellschaft für Chirurgie

20.04. - 23.04.2010, Berlin

Combined use of an improved nucleofection technology and growth factors for pre-clinic therapeutic neovascularization research

Meeting Abstract

  • Ziyang Zhang - Dept. Plastic and Hand Surgery, Klinikum rechts der Isar Technical University of Munich, Deutschland
  • Alex Slobodianski - Dept. Plastic and Hand Surgery, Lübeck University, Lübeck, Deutschland
  • Wulf Ito - Department of Cardiology, Lübeck University, Lübeck, Deutschland
  • Astrid Kathöfer - Dept. Plastic and Hand Surgery, Lübeck University, Lübeck, Deutschland
  • Jessica Frenz - Dept. Plastic and Hand Surgery, Lübeck University, Lübeck, Deutschland
  • Shaoxiang Weng - Department of Cardiology, Lübeck University, Lübeck, Deutschland
  • Natalie Lund - Department of Cardiology, Lübeck University, Lübeck, Deutschland
  • J.Tomas Egana - Dept. Plastic and Hand Surgery, Klinikum rechts der Isar Technical University of Munich, Deutschland
  • Hans-Günther Machens - Dept. Plastic and Hand Surgery, Klinikum rechts der Isar Technical University of Munich, Deutschland

Deutsche Gesellschaft für Chirurgie. 127. Kongress der Deutschen Gesellschaft für Chirurgie. Berlin, 20.-23.04.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. Doc10dgch638

DOI: 10.3205/10dgch638, URN: urn:nbn:de:0183-10dgch6386

Published: May 17, 2010

© 2010 Zhang et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Introduction: Induction of neovascularization by releasing of therapeutic growth factors can be achieved by using gene modified cells. This is a promising application of gene therapy to treat several ischemic related problems. In order to succeed in clinical translation, new experimental approaches have to be developed. In this work, we investigated the feasibility, safeness and effectiveness of a modified nucleofection technology.

Materials and methods: Autologous fibroblasts were nucleofected ex vivo (80% efficiency) to release bFGF and VEGF165 in vivo. After femoral artery ligation, cells were injected intramuscularly in a rat model.

Results: One week post injection, quantitative micro-CT analyses showed that neovascularization was improved in ischemic zone (arteriogenesis:P<0.05; angiogenesis: P<0.05). Improved collateral proliferation (P<0.05) and lower hindlimb blood perfusion (soleus<0.01; gastroenemius: P<0.05) were also observed.Interestingly, a prolonged strong up-regulation of Monocyte Chemotactic Protein-1(MCP-1) was detected by PCR array in the experimental group. Presence of transfected cells at the site of the injection was confirmed by the use of cell tracers. Local confined plasmid expression and transient distributions of the plasmids in other organs were detected by quantitative PCR.

(Figure 1 [Fig. 1])

Conclusion: Our study demonstrates the feasibility and safety of combining a high efficient nucleofection technology and growth factors for large scale pre-clinic neovascularization research.